{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:27:40Z","timestamp":1794619660102,"version":"4.9.1"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>We elucidated the association of serum soluble CD163 (sCD163) with rapidly progressive interstitial lung disease (RP-ILD), autoantibody profiles, and serum ferritin in patients with polymyositis (PM), classic dermatomyositis (DM), and clinical amyopathic dermatomyositis (CADM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Serum sCD163 levels were retrospectively measured by ELISA in patients with PM, classic DM, and CADM, as well as in healthy controls (HC). Repeat sera samples were obtained posttreatment from available patients. The associations between serum sCD163 levels and clinical information were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Serum sCD163 levels in patients with PM\/classic DM\/CADM were significantly higher than those in HC (n = 72, 56, 34, and 68, respectively; p &lt; 0.001 for all comparisons). No significant difference was observed between serum sCD163 levels in patients with and without ILD (p = 0.16) or between those with RP-ILD and chronic ILD (p = 0.21). Serum sCD163 levels were significantly higher in patients with anti-MDA5 antibodies (n = 27) than in those without (p = 0.001). Serum sCD163 levels were weakly correlated with serum ferritin levels in the patients with PM, classic DM, and CADM (r = 0.21). Serum sCD163 levels decreased significantly following treatment in all patient groups (p = 0.003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The present results suggest an association of serum sCD163 with PM, classic DM, and CADM, especially in anti-MDA5 antibody\u2013positive cases. However, serum sCD163 levels were not specifically associated with ILD or RP-ILD.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.170997","type":"journal-article","created":{"date-parts":[[2018,4,15]],"date-time":"2018-04-15T11:35:13Z","timestamp":1523792113000},"page":"947-955","source":"Crossref","is-referenced-by-count":22,"title":["Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody\u2013positive Cases"],"prefix":"10.3899","volume":"45","author":[{"given":"Hidenaga","family":"Kawasumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Hirahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,4,15]]},"reference":[{"key":"2018112909384761000_45.7.947.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket279"},{"key":"2018112909384761000_45.7.947.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.39"},{"key":"2018112909384761000_45.7.947.3","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0246-6"},{"key":"2018112909384761000_45.7.947.4","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909384761000_45.7.947.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.1.22"},{"key":"2018112909384761000_45.7.947.6","doi-asserted-by":"publisher","DOI":"10.1383\/medc.32.3.35.28615"},{"key":"2018112909384761000_45.7.947.7","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0249-3"},{"key":"2018112909384761000_45.7.947.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq149"},{"key":"2018112909384761000_45.7.947.9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrrheum.2016.120","article-title":"Inflammatory myopathies: Choosing the right biomarkers to predict ILD in myositis","volume":"12","author":"Gono","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2018112909384761000_45.7.947.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq073"},{"key":"2018112909384761000_45.7.947.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0371-x"},{"key":"2018112909384761000_45.7.947.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes012"},{"key":"2018112909384761000_45.7.947.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu258"},{"key":"2018112909384761000_45.7.947.14","doi-asserted-by":"crossref","first-page":"815245","DOI":"10.1155\/2014\/815245","article-title":"IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis\/dermatomyositis","volume":"2014","author":"Kawasumi","year":"2014","journal-title":"Biomed Res Int"},{"key":"2018112909384761000_45.7.947.15","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-185"},{"key":"2018112909384761000_45.7.947.16","first-page":"295","article-title":"A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process","volume":"55","author":"Zwadlo","year":"1987","journal-title":"Exp Cell Biol"},{"key":"2018112909384761000_45.7.947.17","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood.V69.5.1320.1320","article-title":"Ki-M8 monoclonal antibody reactive with an intracytoplasmic antigen of monocyte\/macrophage lineage","volume":"69","author":"Radzun","year":"1987","journal-title":"Blood"},{"key":"2018112909384761000_45.7.947.18","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4834"},{"key":"2018112909384761000_45.7.947.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000240242.10583.86"},{"key":"2018112909384761000_45.7.947.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01731.x"},{"key":"2018112909384761000_45.7.947.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.02.005"},{"key":"2018112909384761000_45.7.947.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141307"},{"key":"2018112909384761000_45.7.947.23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","article-title":"Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease","volume":"19","author":"Enomoto","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2018112909384761000_45.7.947.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2018112909384761000_45.7.947.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2018112909384761000_45.7.947.26","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621"},{"key":"2018112909384761000_45.7.947.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg427"},{"key":"2018112909384761000_45.7.947.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621"},{"key":"2018112909384761000_45.7.947.29","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"2018112909384761000_45.7.947.30","doi-asserted-by":"publisher","DOI":"10.1080\/003655102762377466"},{"key":"2018112909384761000_45.7.947.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151317"},{"key":"2018112909384761000_45.7.947.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2459-4"},{"key":"2018112909384761000_45.7.947.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.30113"},{"key":"2018112909384761000_45.7.947.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170165"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T21:18:31Z","timestamp":1571174311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,15]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,1]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.3899\/jrheum.170997"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170997","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,15]]}}}